Banner background image Banner background image
Banner background image Banner background image
Banner background image Banner background image

SUPPORTING ACCESS

  • FOR YOUR PRACTICE

  • FOR YOUR PATIENTS

  • ACQUIRING LEQVIO®

YOUR DEDICATED TEAM PROVIDES SUPPORT FOR YOU
AND YOUR PATIENTS

Visit the LEQVIO Service Center

LEQVIO® Service Center

Visit the LEQVIO Service Center

LEQVIO® Service Center

Your single point of contact is a dedicated specialist who can handle all your inquiries and requests for LEQVIO.

LEQVIO-access.com | 1-833-LEQVIO2 M-F 8:00 AM to 8:00 PM (ET)

  • Provides support with insurance, coding & billing, and patient savings options

Find your dedicated specialist and contact information

Access & Reimbursement Manager

Available for in-office visits or by phone.

  • Offers resources and educational information on acquisition and coding & billing

Get patients started on LEQVIO: Assistance with the product acquisition and reimbursement processes

Self-Service Website

  • Comprehensive resources on acquisition, affordability, reimbursement, and all patient support programs

  • Alternate Injection Center Locator Tool

  • Live Click-to-Chat

VISIT
LEQVIO-ACCESS.COM arrow
Contact a Sales Specialist

SALES SPECIALIST

Contact a Sales Specialist

SALES SPECIALIST

  • Provide clinical product information

  • Sales Specialists do not have access to patient-level data

  • Review general acquisition information

  • Offer information regarding
    co-pay and adherence
    support options

  • Sales Specialists do not have access to patient‑level data

CONTACT A SALES
SPECIALIST arrow

BROADLY COVERED AND AFFORDABLE FOR MOST PATIENTS4*

Because it is given by an HCP, LEQVIO® is covered primarily under the medical benefit,
not the pharmacy benefit

FOR TRADITIONAL MEDICARE
PATIENTS4

LEQVIO co-pay card

COVERED, AFFORDABLE

NO PRIOR AUTHORIZATION REQUIRED

LEQVIO co-pay card

Have supplemental
plans and

MAY PAY AS LITTLE AS $0

MAY PAY AS LITTLE AS $0

Some supplemental plans may require precertification or prior authorization

LEQVIO co-pay card

PART B medical benefit

Not subject to the Part D pharmacy
benefit donut hole

Not subject to the Part D pharmacy benefit donut hole

FOR COMMERCIAL AND
MEDICARE PATIENTS4

LEQVIO co-pay card

COVERED

LEQVIO co-pay card

have confirmed coverage on the

MEDICAL BENEFIT FOR LEQVIO

MEDICAL BENEFIT FOR LEQVIO

LEQVIO co-pay card

patients' medical insurance plans

DO NOT REQUIRE A STEP
THROUGH ANOTHER INJECTABLE

DO NOT REQUIRE A STEP
THROUGH ANOTHER INJECTABLE

HIGHER APPROVAL RATES

when appropriately submitted under the MEDICAL BENEFIT

Most patients PAY 36% LESS FOR LEQVIO® vs other branded nonstatin treatments4‡

medical benefit

Actual claims data from January to December 2022

  • Based on 2100+ medical and pharmacy claims, excluding low-income subsidy patients

  • Patient monthly OOPs represent actual yearly cost divided by 12 to reflect an average monthly cost

LEQVIO co-pay card
LEQVIO co-pay card

AFFORDABLE

LEQVIO co-pay card

MAY PAY AS
LITTLE AS $0

PATIENTS PAY
LEQVIO co-pay cardLESS

out-of-pocket annually vs other branded nonstatin treatments, including PCSK9 mAbs

Approval rates for LEQVIO® are higher when claims are submitted appropriately under the medical benefit

Actual claims data from January to December 2022

  • Based on 2100+ medical and pharmacy claims, excluding low-income
    subsidy patients

medical benefit

*Coverage information is subject to change by the relevant plan and is based on data up to July 2023. The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims.4

The comparison pertains only to differences in cost and should not be considered a comparison of efficacy or safety.4

Branded nonstatin treatments include Repatha, Nexlizet, Nexletol, and Praluent.

§Patient out-of-pocket cost calculated from annualized medical and pharmacy claims. Monthly out-of-pocket per brand is based on weighted average of prescribed dose per patient. Data current as of July 2023.

Includes Traditional Medicare, Medicare Advantage, and Commercial plans.

$0 Co-pay Savings

Eligible privately insured patients may pay as little as $0 for LEQVIO with the co-pay savings offer. Subject to terms and conditions. Limitations apply.#

Eligible privately insured new patients may be able to receive up to two (2) free doses if coverage is delayed or denied. Limitations apply.**

0$ Co-Pay

LEQVIO Care Program

www.careprogram.leqvio.com | 1-833-LEQVIO2

When enrolled, patients on therapy have access to:

- One-on-one support by LEQVIO Care Specialists

- Injection appointment reminders

- Helpful tools, lifestyle tips, and motivation through text,
  mail, and email

The LEQVIO Care Program is a patient support program and is not intended to take the place of medical or clinical advice from a health care provider.

0$ Co-Pay

#Eligible patients must have commercial insurance, a valid prescription for LEQVIO, and a prior authorization that has been denied or pending for greater than 3 calendar days. Program provides up to two (2) doses of free medication. Program is not available to patients who are uninsured or whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program, or where prohibited by law. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Other limitations may apply. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

**Limitations apply. Valid only for those with commercial insurance. The Program may include the Co-pay Card, Payment Card (if applicable), and Rebate, with a per treatment benefit maximum of $1800 and an annual benefit limit of $2400. Per treatment maximums and an annual benefit cap apply. For patients covered under the medical benefit, rebate for out-of-pocket costs will be assigned directly to provider, unless patient requests direct reimbursement. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

You can enroll your patients in 3 different ways:

Download and fax our 1-page

start form to 1-877-LEQVIO8

(1-877-537-8468)

Download the LEQVIO
Patient Start Form

Enroll your patients electronically
via ServiceCenterPortal.com for
all services, including co-pay

VISIT SERVICE
CENTER PORTAL arrow

Enroll your patients electronically
via LEQVIO-CoPayPortal.com for
co–pay–only support

VISIT
LEQVIO-COPAY PORTAL.COM arrow

LOOKING FOR MORE
INFORMATION
FOR
YOUR PATIENTS?

THE CHOICE IS YOURS

Flexible pathways for acquisition and administration

IN-OFFICE
ADMINISTRATION

Acquire LEQVIO through buy-and-bill or a specialty pharmacy

BUY-AND-BILL

  • Office purchases LEQVIO from distributor

  • Office submits a claim for reimbursement for the cost of LEQVIO and administration

SPECIALTY PHARMACY

  • Office submits a LEQVIO prescription to the specialty pharmacy

  • Specialty pharmacy sends product to the office

  • Once LEQVIO is administered, office submits a claim for cost of administration but not of product

OUT-OF-OFFICE
ADMINISTRATION

Refer patient to an Alternate Site of Care for injection

ALTERNATE SITE OF CARE

  • Alternate Site of Care handles ordering LEQVIO, administration, and reimbursement for all services

  • Office does not purchase or bill for LEQVIO

  • Office purchases LEQVIO from distributor

  • Office submits a claim for reimbursement for the cost of LEQVIO and administration

  • Office submits a LEQVIO prescription to the specialty pharmacy

  • Specialty pharmacy sends product to the office

  • Once LEQVIO is administered, office submits a claim for cost of administration but not of product

  • Alternate Site of Care handles ordering LEQVIO, administration, and reimbursement for all services

  • Office does not purchase or bill for LEQVIO

Have questions?

Contact your Access & Reimbursement Manager

or talk to an Access Specialist at either:

Phone: 833-LEQVIO2 (833-537-8462)

Fax: 877-LEQVIO8 (877-537-8468)

Web: LEQVIO-access.com

Portal: ServiceCenterPortal.com

IN-OFFICE ADMINISTRATION

Acquire LEQVIO through buy-and-bill
or an SP

BUY-AND-BILL

Administration takes place in
your office (Medical Benefit)

  • Buy-and-bill is an option for acquiring drugs covered under the medical benefit that are administered by a health care provider

  • Drugs covered under Medicare Part B (fee-for-service) must be acquired through this method

FIND OUT MORE
ABOUT BUY-AND-BILL arrow

SPECIALTY PHARMACY

Administration takes place within your office via an SP

  • A patient's plan may restrict drug coverage under the pharmacy benefit using an SP

  • LEQVIO ordered through an SP must be given to the specific patient for whom it was ordered (unlike the buy-and-bill, in which LEQVIO can be given to any patient for whom it's prescribed)

VISIT LEQVIO
SERVICE CENTER arrow

OUT-OF-OFFICE
ADMINISTRATION

Send order to an AIC, which manages
LEQVIO acquisition via buy-and-bill

ALTERNATE INJECTION CENTER (AIC)

Administration takes place at a site other than your office*

  • Practice locates and refers the patient to an Alternate Site of Care, which then handles the following:
    - Benefits verification
    - Prior authorization support
    - Acquisition of LEQVIO
    - Administration of LEQVIO
    - Submitting claims for reimbursement

  • A system hospital outpatient department (HOPD) may act as an Alternate Site of Care. It's important to understand system requirements before sending the LEQVIO patient to that facility

FIND AN ALTERNATE SITE OF CARE* arrow

*May include a clinic, hospital outpatient department, or another physician's office.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND IMPORTANT SAFETY
INFORMATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Integrated Summary of Efficacy. Novartis Pharmaceuticals Corp. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.